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Rat proglucagon(64-69) corresponding to the C-terminal hexapeptide of putative rat glicentin sequence in 
the precursor was synthesized. A glicentin C-terminal hexapeptide specific radioimmunoassay, using the 
synthetic hexapeptide as standard, demonstrated the presence in rat pancreas of a peptide identified with 
the synthetic rat proglucagon(6469): H-Asn-Arg-Asn-Asn-Ile-Ala-OH. The hexapeptide was released con- 
comitantly with glucagon by arginine stimulation from the isolated perfused rat pancreas. The results in- 
dicate that the pancreas co-stores and possibly co-releases the hexapeptide with glucagon as one of the pro- 
cessing products of proglucagon. 
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1. INTRODUCTION 
A recent study of the rat glucagon gene deduced 
an amino acid sequence for rat preproglucagon [ 11. 
This information has made it possible to examine 
molecular processing of the rat glucagon precursor 
in pancreatic tissue employing synthetic peptides. 
This study demonstrates that rat pancreas contains 
a peptide identified with synthetic H-Asn-Arg- 
Asn-Asn-Ile-Ala-OH corresponding to putative rat 
glicentin(64-69); arginine stimulation enhanced 
the release of this hexapeptide and glucagon from 
isolated perfused rat pancreas. 
2. MATERIALS AND METHODS 
2.1. Peptides 
Rat proglucagon(64-69) corresponding to 
putative rat glicentin(64-69) was newly synthe- 
sized by a solid-phase technique [2] employing a 
Beckman 990B peptide synthesizer. Purity of the 
o To whom correspondence should be addressed 
hexapeptide was assessed by routine analytical 
criteria. Amino acid ratios in an acid hydrolysate 
(6 N HCl, llO”C, 24 h) of the peptide were: Asp, 
3.02; Ala, 1 JO; Be, 1.04; Arg, 0.93; and in 
aminopeptidase M digest Asn, 2.83; Ala, 1.08; Ile, 
1.05; Arg, 1.03. Other synthetic peptides used were 
those described previously [3]. 
2.2. Tissue extraction 
Male Wistar rats (200-250 g) were decapitated 
and the pancreas was removed. Pancreatic tissue 
was homogenized with a 5-fold excess of ice-cold 
0.1 M acetic acid. The homogenate was heated in 
a boiling water bath for 5 min and cooled after 
which the final acetic acid concentration was ad- 
justed to 1 M. The homogenate was centrifuged at 
1400 x g for 20 min at 4°C. The precipitate was 
washed with 1 M acetic acid and the combined 
supernatant and washing were lyophilized. 
2.3. Gel filtration 
The crude extract of rat pancreas was 
chromatographed upon Sephadex-GSOF (column 
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1.5 x 91 cm) eluted with 3 M acetic acid. Column 
fractions (2.5 ml) were collected, lyophilized and 
reconstituted with assay buffer. 
2.4. High performance liquid chromatography 
(HPLC) 
Reverse-phase HPLC was performed on a Toyo- 
Soda SP8700 high speed liquid chromatograph. 
Rat pancreas crude extract and synthetic peptides 
were chromatographed on a Nucleocil 5Cls col- 
umn (M. Nagel, Diiren, FRG) (4.6 x 250 mm) in 
a gradient solvent system of CHjOH/O.Ol N HCI 
(O:lOO-10:90, v/v, for 30 min and 10:90-50:50 
for 40 min) at a flow rate of 1 ml/min. The eluate 
was collected every min, lyophilized and 
reconstituted with assay buffer. 
2.5. Isolated perfused rat pancreas 
Overnight-fasted male Wistar rats (200-250 g) 
were anesthetized with sodium pentobarbital. The 
pancreas was removed and perfused according to 
Grodsky and Fanska [4]. The pancreas was per- 
fused with Krebs-Ringer bicarbonate (KRB) buffer 
(pH 7.4), supplemented with 4(r/o Dextran T70 
(Pharmacia, Uppsala, Sweden) and 0.2% bovine 
serum albumin (BSA) (Sigma, St. Louis, MO). The 
perfusion medium was equilibrated with 95% 
02 : 5% CO2 and the flow rate was maintained at 
1.9 ml/min. During the first 25 min, glucose (final 
concentration 5.5 mM) was introduced via a side- 
arm syringe at a flow rate of 0.1 ml/min. Glucose 
was replaced with arginine (final concentration 
15 mM) for a 20 min period. The pancreas was 
perfused with glucose again for the last 10 min. 
After the first 15 min equilibration period with 
glucose, the perfusate was collected every min in 
tubes containing 1000 KIU Trasylol (Bayer, 
Leverkusen, FRG). Hexapeptide and pancreatic 
glucagon contents of each perfusate sample were 
determined by specific radioimmunoassays. In the 
other experiment, isolated rat pancreas was per- 
fused with arginine (final concentration 10 mM) in 
the presence of glucose (final concentration 
5.5 mM) for 20 min after 25-min preperfusion 
with glucose (final concentration 5.5 mM). 
2.6. Radioimmunoassay 
Radioimmunoassay for rat glicentin C-terminal 
hexapeptide was performed according to [3] using 
antiserum R4804 [5], 1251-3-(4-hydroxyphenyl)pro- 
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pionyl-porcine glicentin(62-69) as tracer and rat 
glicentin(64-69) as standard. 
Pancreatic glucagon specific radioimmunoassay 
was carried out as described using antisera 
OAL-123 [6]. 
3. RESULTS 
In the radioimmunoassay specific for 
glicentin(64-69), the newly synthesized putative 
rat glicentin(64-69) displaced the tracer in a man- 
ner parallel to that of porcine glicentin(64-69) 
(fig. 1). The relative cross-reactivity of the rat pep- 
tide was 37.8% of the porcine hexapeptide in this 
system. Crude extracts of 3 rat pancreases all 
possessed ilution curves parallel to the standard 
curve of synthetic rat glicentin(64-69) (fig. 1). The 
gel filtration profile of the immunoreactivity in 
crude extract of rat pancreas is shown in fig.2a. 
The integrated immunoreactivity in the main peak 
extract dilution 
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Fig. 1. Dose-response curves of synthetic rat and porcine 
glicentin(64-69) fragments and dilution curves of crude 
extracts of 3 different rat pancreas specimens in 
radioimmunoassay system with antiserum R4804 and 
‘ZSI-3-(4-hydroxyphenyI)propionyl-porcine glicentin- 
(62-69) as tracer. (M) Synthetic rat glicentin(64- 
69), (+-o) synthetic porcine glicentin(M-69) and 
([It--o, H , A--A) rat pancreatic crude extracts. 
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Fig.2. Gel filtration profiles of (a) immunoreactive 
hexapeptide and (b) immunoreactive pancreatic 
glucagon in crude rat pancreatic extracts. 
fractions corresponding to the hexapeptide ac- 
counts for 81.5% of the total immunoreactivity 
detected in the crude extract and it corresponded to 
132’70, on a molar basis, of pancreatic glucagon 
immunoreactivity in the same extract which was 
calculated from the elution profile shown in fig.2b. 
The hexapeptide peak fractions were collected and 
successively analyzed by HPLC. The immunoreac- 
tivity eluted as a single peak (fig.3a). The retention 
time was exactly the same as that of synthetic rat 
glicentin(64-69) (fig.3c) and distinctly different 
from that of synthetic porcine glicentin(64-69) 
(fig.3b). 
Fig.4 shows arginine-stimulated release of 
glicentin C-terminal hexapeptide immunoreactivity 
from the isolated perfused rat pancreas. Release of 
the hexapeptide immunoreactivity in the presence 
of 15 mM arginine was biphasic and parallel to the 
release of glucagon. Glucose suppressed the release 
of both hexapeptide and glucagon. Total response 
of the hexapeptide was 105%, on a molar basis, of 
the total pancreatic glucagon released. No ap- 
preciable release of the hexapeptide immunoreac- 
tivity was observed when 10 mM arginine was in- 
fused in the presence of 5.5 mM glucose. 
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Fig.3. Identification in HPLC of the hexapeptide in rat 
pancreas extract with synthetic peptides. HPLC profiles 
of (a) the hexapeptide-like immunoreactive component 
in rat pancreas (80 ng equivalent), (b) a mixture of the 
hexapeptide-like immunoreactive component in rat 
pancreas (80 ng equivalent) and synthetic porcine 
glicentin(64-69) (200 ng) and (c) a mixture of the 
hexapeptide-like immunoreactive component in rat 
pancreas (80 ng equivalent) and synthetic rat glicen- 
tin(64-69) (200 ng). 
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Fig.4. Arginine-stimulated release of (+----o) glicentin 
C-terminal hexapeptide and (O-Q) pancreatic 
glucagon from isolated perfused rat pancreas. n = 5. 
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4. DISCUSSION 
In a previous study [7], we isolated a 
glicentin(64-69) fragment from porcine pancreas 
using a radioimmunoassay specific for the hex- 
apeptide [3] and presented evidence for the ex- 
istence of the hexapeptide fragment in porcine 
pancreas with glucagon on approximately an 
equimolar basis. Recent presentation of a putative 
amino acid sequence for rat preproglucagon, 
deduced from the gene sequence [l], promoted the 
tat as an experimental model for studying 
molecular processing of proglucagon. Based on the 
proposed structure of the precursor, we synthe- 
sized a putative rat glicentin(64-69) and developed 
a radioimmunoassay for the rat hexapeptide. The 
assay system measured rat hexapeptide-related 
materials. 
The hexapeptide in rat pancreas was identified 
with synthetic H-Asn-Arg-Asn-Asn-Ile-Ala-OH by 
HPLC and differed from the porcine peptide H- 
Asn-b-Asn-Asn-Ile-Ala-OH. The hexapeptide 
was the major component in a crude rat pancreatic 
extract measurable with the current hexapeptide 
assay and only a small amount of glicentin- and 
oxyntomodulin-like components was detected. The 
molar ratio of the hexapeptide and pancreatic 
glucagon in the same extract which was calculated 
from the gel filtration profile was approx. 1 : 0.75. 
The extraction efficiency of glucagon, but not the 
hexapeptide, in rat pancreas with hot dilute acetic 
acid was found to be lower, approx. 64070, when 
compared with acid-alcohol extraction as has been 
observed with porcine pancreas [5,7]. On the basis 
of this figure, the hexapeptide in rat pancreatic ex- 
tract was assumed to correspond to 85% pan- 
creatic glucagon on a molar basis. This was com- 
patible with our previous result with porcine pan- 
creas [7] and suggests approximately equimolar 
production of the hexapeptide and glucagon in rat 
pancreas. 
From the isolated perfused rat pancreas, the 
hexapeptide was released concomitantly with pan- 
creatic glucagon by 15 mM arginine stimulation. 
The total response of the hexapeptide and 
glucagon indicated concomitant release of approx- 
imately equimolar amounts of both peptides under 
the condition used. Based on the specificity of the 
hexapeptide radioimmunoassay employed and the 
values measured, the immunoreactivity recognized 
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in the perfusates by the hexapeptide-specific assay 
system was reasonably attributable mainly to the 
hexapeptide itself. 
We have demonstrated [5] immunohistochemi- 
tally the existence, in the CY granules of human pan- 
creatic A cells, of glicentin C-terminal immunore- 
activity stained with antiserum R4804. Together 
with the present results, it seems reasonable to con- 
clude that in addition to the N-terminal fragment 
of glicentin, GRPP [8], the pancreas co-stores and 
possibly co-releases the hexapeptide with glucagon 
as one of the processing products of proglucagon. 
Whether the hexapeptide and glucagon are re- 
leased under physiological conditions and a poten- 
tial physiological role for the hexapeptide itself re- 
main to be investigated. 
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